Oppenheimer initiated coverage of BioNTech with a Perform rating and no price target. The firm expects COVID-19 sales to continue decreasing in 2024, with sales growth possibly reoccurring in 2025 onward as it assumes mRNA flu vaccine approval in 2025 and late-stage oncology candidates to launch mid-decade, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BNTX:
- Florida surgeon general calls for halt to use of mRNA Covid-19 vaccines
- BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Endometrial Cancer
- BioNTech, DualityBio receive FDA BTD for BNT323/DB-1303
- CureVac price target lowered to $6.40 from $8 at BofA
- CureVac announces German Federal Patent Court decision in BioNTech litigation